The research group led by Isidro Sánchez of the Cancer Research Center (IBMCC) defined in detail the genetic pattern of follicular lymphoma and its evolution in 2015.
In the work, they were able to identify mutated genes in 96% of follicular lymphoma tumors, where the Crebbp gene was shown to play a prominent role. When a specific mutation is detected in almost all cases, the scientific community tries to demonstrate that the mutation is relevant and could even be at the origin of the disease studied.
In this sense, the Crebbp gene has allowed scientists to explain the mechanism of evolution of follicular lymphoma and promises to be a good molecular target for the development of drugs. Specifically, the new publication shows that in cases where the Crebbp gene undergoes a deletion, i.e. when loss occurs, diffuse large B-cell lymphoma is generated. In contrast, when Crebbp is mutated, i.e. when the sequence is altered, follicular lymphoma is generated. In short, depending on this flaw, one or the other disease is generated .
Therefore, this progress improves understanding of the origin of follicular lymphoma and diffuse large B-cell lymphoma, unknown to date, and will open the door to developing new drugs that inhibit Myc, since the loss of transcriptional and epigenetic Crebbp signatures has been shown to involve the Myc gene in the etiology of the disease.
More information: Comunicación Universidad de Salamanca
news published in the media:
